Background:Antiretroviral therapy(ART)was often associated with dyslipidemia among human immunodeficiency virus(HIV)/acquired immunodeficiency syndrome(AIDS)patients.This study aimed to assess treatment-naïve adu...Background:Antiretroviral therapy(ART)was often associated with dyslipidemia among human immunodeficiency virus(HIV)/acquired immunodeficiency syndrome(AIDS)patients.This study aimed to assess treatment-naïve adult male patients with HIV/AIDS who initiated ART with either co-formulated bictegravir,emtricitabine,and tenofovir alafenamide(BIC/FTC/TAF)or lamivudine,efavirenz,and tenofovir disoproxil fumarate(3TC+EFV+TDF),monitoring at weeks 4,12,24,and 48.Methods:A case-control retrospective study was conducted.The newly diagnosed HIV-infected individuals attending the sexual transmission disease(STD)/AIDS clinic of Beijing Youan Hospital,Capital Medical University,from January to December 2021.The patients were divided into BIC/FTC/TAF group or 3TC+EFV+TDF group.High-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),triglyceride(TG),and total cholesterol(TC)at different time points over 48 weeks between two groups were compared.A multivariate Cox regression model was used to identify relevant influencing factors for the population at high risk of increased LDL-C.Results:A total of 870 participants,with 510 in BIC/FTC/TAF group and 360 in 3TC+EFV+TDF group.There were no statistically significant differences in median age,baseline CD4/CD8 ratio,median body mass index(BMI)between the two groups.In both two groups,levels of TG,TC,and LDL-C were higher at 4 weeks,12 weeks,and 24 weeks of treatment(all P<0.05),and there were no statistically significant differences at 48 weeks compared to those at baseline(all P>0.05).In addition,the differences in average changes of the level of TG,TC,HDL-C,and LDL-C from weeks 4,12,24,and 48 to baseline between two groups were not statistically significant(all P>0.05).Multivariate Cox proportional risk model analysis showed that initiating ART with HIV RNA≥10^(5)copies/mL(compared with<10^(5)copies/mL)was associated with an increased risk of elevated LDL-C(hazard ratio=1.26,95%confidence interval:1.07-1.48,P=0.005).Conclusions:Transient elevations in blood lipid levels(TC,TG,HDL-C,and LDL-C)were observed in treatment-naïve adult male HIV/AIDS patients with BIC/FTC/TAF at 4 weeks,12 weeks,and 24 weeks of treatment.However,these levels did not differ significantly from baseline after 48 weeks of treatment,regardless of whether patients were in the BIC/FTC/TAF or 3TC+EFV+TDF group.展开更多
目的:探究艾滋病(AIDS)患者使用高效抗反转录病毒疗法(highly active antiretroviral therapy,HAART)后的安全性及其疗效。方法:选择2011年5月至2014年5月在我院进行免费HAART治疗的27例HIV-1晚期患者,即用替诺福韦+拉米夫定+依非韦伦...目的:探究艾滋病(AIDS)患者使用高效抗反转录病毒疗法(highly active antiretroviral therapy,HAART)后的安全性及其疗效。方法:选择2011年5月至2014年5月在我院进行免费HAART治疗的27例HIV-1晚期患者,即用替诺福韦+拉米夫定+依非韦伦的药物治疗,疗程为1~2年,平均18个月。其后进行了6个月到2年的随访,定期监测HIV-RNA病毒载量、CTL(HIV特异性细胞毒性T淋巴细胞)应答、CD4+T淋巴细胞计数、常规生化指标和临床观察指标等。结果:27例患者临床症状均明显改善,70.4%(19/27)的患者HIV-RNA病毒载量<50拷贝/m L,CD4+T淋巴细胞计数平均为276±129个/μL,CTL在每个蛋白区均有较高应答频率和相关效应。常规生化指标和临床观察指标基本恢复正常。结论:HAART有较好的抗病毒疗效,免疫重建效果也很好,可以大大降低艾滋病的机会感染和死亡率,提高病人的生活质量。展开更多
基金supported by the Gilead Sciences and the Capital Health Research and Development of Special Fund(No.2022-1G-3015)
文摘Background:Antiretroviral therapy(ART)was often associated with dyslipidemia among human immunodeficiency virus(HIV)/acquired immunodeficiency syndrome(AIDS)patients.This study aimed to assess treatment-naïve adult male patients with HIV/AIDS who initiated ART with either co-formulated bictegravir,emtricitabine,and tenofovir alafenamide(BIC/FTC/TAF)or lamivudine,efavirenz,and tenofovir disoproxil fumarate(3TC+EFV+TDF),monitoring at weeks 4,12,24,and 48.Methods:A case-control retrospective study was conducted.The newly diagnosed HIV-infected individuals attending the sexual transmission disease(STD)/AIDS clinic of Beijing Youan Hospital,Capital Medical University,from January to December 2021.The patients were divided into BIC/FTC/TAF group or 3TC+EFV+TDF group.High-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),triglyceride(TG),and total cholesterol(TC)at different time points over 48 weeks between two groups were compared.A multivariate Cox regression model was used to identify relevant influencing factors for the population at high risk of increased LDL-C.Results:A total of 870 participants,with 510 in BIC/FTC/TAF group and 360 in 3TC+EFV+TDF group.There were no statistically significant differences in median age,baseline CD4/CD8 ratio,median body mass index(BMI)between the two groups.In both two groups,levels of TG,TC,and LDL-C were higher at 4 weeks,12 weeks,and 24 weeks of treatment(all P<0.05),and there were no statistically significant differences at 48 weeks compared to those at baseline(all P>0.05).In addition,the differences in average changes of the level of TG,TC,HDL-C,and LDL-C from weeks 4,12,24,and 48 to baseline between two groups were not statistically significant(all P>0.05).Multivariate Cox proportional risk model analysis showed that initiating ART with HIV RNA≥10^(5)copies/mL(compared with<10^(5)copies/mL)was associated with an increased risk of elevated LDL-C(hazard ratio=1.26,95%confidence interval:1.07-1.48,P=0.005).Conclusions:Transient elevations in blood lipid levels(TC,TG,HDL-C,and LDL-C)were observed in treatment-naïve adult male HIV/AIDS patients with BIC/FTC/TAF at 4 weeks,12 weeks,and 24 weeks of treatment.However,these levels did not differ significantly from baseline after 48 weeks of treatment,regardless of whether patients were in the BIC/FTC/TAF or 3TC+EFV+TDF group.
文摘目的:探究艾滋病(AIDS)患者使用高效抗反转录病毒疗法(highly active antiretroviral therapy,HAART)后的安全性及其疗效。方法:选择2011年5月至2014年5月在我院进行免费HAART治疗的27例HIV-1晚期患者,即用替诺福韦+拉米夫定+依非韦伦的药物治疗,疗程为1~2年,平均18个月。其后进行了6个月到2年的随访,定期监测HIV-RNA病毒载量、CTL(HIV特异性细胞毒性T淋巴细胞)应答、CD4+T淋巴细胞计数、常规生化指标和临床观察指标等。结果:27例患者临床症状均明显改善,70.4%(19/27)的患者HIV-RNA病毒载量<50拷贝/m L,CD4+T淋巴细胞计数平均为276±129个/μL,CTL在每个蛋白区均有较高应答频率和相关效应。常规生化指标和临床观察指标基本恢复正常。结论:HAART有较好的抗病毒疗效,免疫重建效果也很好,可以大大降低艾滋病的机会感染和死亡率,提高病人的生活质量。